JP2018502286A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502286A5
JP2018502286A5 JP2017526884A JP2017526884A JP2018502286A5 JP 2018502286 A5 JP2018502286 A5 JP 2018502286A5 JP 2017526884 A JP2017526884 A JP 2017526884A JP 2017526884 A JP2017526884 A JP 2017526884A JP 2018502286 A5 JP2018502286 A5 JP 2018502286A5
Authority
JP
Japan
Prior art keywords
biomarkers
subject
level
sample
liver disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017526884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018502286A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/061215 external-priority patent/WO2016081534A1/en
Publication of JP2018502286A publication Critical patent/JP2018502286A/ja
Publication of JP2018502286A5 publication Critical patent/JP2018502286A5/ja
Pending legal-status Critical Current

Links

JP2017526884A 2014-11-19 2015-11-18 脂肪肝疾患のバイオマーカーおよびその使用方法 Pending JP2018502286A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462081903P 2014-11-19 2014-11-19
US62/081,903 2014-11-19
US201562141494P 2015-04-01 2015-04-01
US62/141,494 2015-04-01
PCT/US2015/061215 WO2016081534A1 (en) 2014-11-19 2015-11-18 Biomarkers for fatty liver disease and methods using the same

Publications (2)

Publication Number Publication Date
JP2018502286A JP2018502286A (ja) 2018-01-25
JP2018502286A5 true JP2018502286A5 (enExample) 2018-12-27

Family

ID=56014479

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017526884A Pending JP2018502286A (ja) 2014-11-19 2015-11-18 脂肪肝疾患のバイオマーカーおよびその使用方法

Country Status (5)

Country Link
US (1) US20170370954A1 (enExample)
EP (1) EP3221463A4 (enExample)
JP (1) JP2018502286A (enExample)
CN (1) CN107002113A (enExample)
WO (1) WO2016081534A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170193810A1 (en) * 2016-01-05 2017-07-06 Wizr Llc Video event detection and notification
WO2017210147A1 (en) 2016-05-29 2017-12-07 Wei Jia Liver disease-related biomarkers and methods of use thereof
DK3465202T3 (da) * 2016-06-02 2023-08-21 Metabolon Inc Massespektrometrifremgangsmåde til detektering og kvantitering af metabolitter
WO2018007422A1 (en) * 2016-07-05 2018-01-11 One Way Liver,S.L. Identification of human non-alcoholic fatty liver disease (nafld) subtypes
EP3267199A1 (en) * 2016-07-06 2018-01-10 One Way Liver S.L. Diagnostic methods based on lipid profiles
US12313634B2 (en) 2017-11-20 2025-05-27 Zora Biosciences Oy Methods for prediction and early detection of diabetes
EP3502703A1 (en) 2017-12-22 2019-06-26 Metanomics Health GmbH Method for the assessment of nafld
CA3095403A1 (en) * 2018-04-04 2019-10-10 Metabolon, Inc. Mass spectrometry assay method for detection and quantitation of liver function metabolites
WO2019246107A1 (en) * 2018-06-18 2019-12-26 Duke University Metabolic biomarkers of nafld/nash and related disease phenotypes and methods of using same
JP7029139B2 (ja) * 2018-08-23 2022-03-03 デンカ株式会社 非アルコール性脂肪性肝炎の検出を補助する方法
WO2020044497A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
WO2020044500A1 (ja) * 2018-08-30 2020-03-05 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
WO2020066162A1 (ja) * 2018-09-26 2020-04-02 株式会社島津製作所 非アルコール性脂肪肝疾患の検出方法、非アルコール性脂肪肝疾患検出用キットおよび非アルコール性脂肪肝疾患検出用バイオマーカー
KR102105880B1 (ko) * 2018-10-26 2020-04-29 서울대학교병원 비알코올 지방간 질환의 조직학적 중증도 진단 또는 예후 측정에 관한 정보 제공 방법
WO2020126780A1 (en) * 2018-12-19 2020-06-25 Astrazeneca Ab Biomarker of pnpla3 expression
JP6592627B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 Ｎａｆｌｄ又はｎａｓｈの検出又はリスクの予測方法、ｎａｆｌｄ又はｎａｓｈを検出するための診断薬キット、対象における肝線維化の進行度の判定方法、及び対象における肝線維化の進行度を判定するための診断薬キット
JP6592628B1 (ja) * 2019-03-12 2019-10-16 国立大学法人 東京大学 脂肪性肝疾患の検出又はリスクの予測方法、脂肪性肝疾患を検出するための診断薬キット及びバイオマーカー、対象の肝線維化の進行度の判定方法、並びに対象の肝線維化の進行度を判定するためのバイオマーカー
KR102280261B1 (ko) * 2019-07-16 2021-07-20 이화여자대학교 산학협력단 대사체 분석을 이용한 간질환의 진단 방법
CN110507670B (zh) * 2019-09-24 2023-04-07 江西天元药业有限公司 精制熊胆粉及预防治疗肝病肝纤维化改善肝功能的用途
US20230064246A1 (en) * 2019-11-05 2023-03-02 Beth Israel Deaconess Medical Center, Inc. Diagnosis and treatment of nafld and liver fibrosis
US12571806B2 (en) * 2020-02-04 2026-03-10 Denka Company Limited Method for assisting detection of non-alcoholic steatohepatitis
CN111562321B (zh) * 2020-04-16 2022-10-28 广东省结核病控制中心 用于检测活动性肺结核的粪便代谢物及其检测系统
CN117597583A (zh) * 2021-03-18 2024-02-23 康博国际有限公司 检测和定量体液样品的大量分子生物标志物的方法和系统
CN112712896B (zh) * 2021-03-26 2023-03-07 深圳市绘云生物科技有限公司 用于受试体检测非酒精性脂肪性肝病状态的诊断装置及计算机系统
CN113160983A (zh) * 2021-04-09 2021-07-23 南京医科大学附属逸夫医院 一种代谢相关脂肪性肝病临床预测模型
WO2023097510A1 (zh) * 2021-11-30 2023-06-08 江苏品生医疗科技集团有限公司 预测受试者患有糖尿病的可能性的标记物及其应用
JPWO2023238881A1 (enExample) * 2022-06-07 2023-12-14
WO2024237259A1 (ja) * 2023-05-17 2024-11-21 株式会社島津製作所 非アルコール性脂肪肝疾患の発症リスク評価方法、および、バイオマーカー
CN121195170A (zh) * 2023-05-17 2025-12-23 株式会社岛津制作所 非酒精性脂肪性肝病的识别方法和生物标志物
WO2025008464A2 (en) 2023-07-06 2025-01-09 Numares Ag Use of a marker or a marker set for determining the risk of an individual to have ascites
EP4739389A2 (en) 2023-07-06 2026-05-13 Numares AG Use of a marker or a marker set for determining the risk of an individual to have a reduced liver function
EP4740022A1 (en) 2023-07-06 2026-05-13 Numares AG Use of a biomarker for determining the risk of an individual to have hepatic encephalopathy
EP4740021A2 (en) 2023-07-06 2026-05-13 Numares AG Use of a biomarker for determining the child-pugh class into which an individual is to be classified
EP4653872A1 (en) * 2024-05-22 2025-11-26 Cristóbal Manuel Richart Jurado A set of biomarkers and an in vitro method for the diagnosis of metabolic dysfunction-associated steatohepatitis (mash)
WO2026083345A1 (en) * 2024-10-18 2026-04-23 Universita' Degli Studi Di Torino A new model for the diagnosis of liver fibrosis in patients with metabolic dysfunction-associated steatotic liver disease
CN119506412B (zh) * 2024-11-01 2026-02-24 上海爱谱蒂康生物科技有限公司 一种生物标志物组合及其在预测帕金森病中的应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329489B2 (en) 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
JP2003530130A (ja) 2000-04-14 2003-10-14 メタボロン インコーポレイテッド メタボロミクスを使用した薬物発見、疾患の処置、及び診断のための方法
WO2005052575A1 (en) * 2003-11-28 2005-06-09 Pfizer Limited Molecular markers of oxidative stress
US7856319B2 (en) * 2005-02-03 2010-12-21 Assistance Publique-Hopitaux De Paris (Ap-Hp) Diagnosis method of alcoholic steato-hepatitis using biochemical markers
JP5496650B2 (ja) 2006-03-21 2014-05-21 メタボロン インコーポレイテッド サンプル内の個々の要素を識別及び定量化するために分光測定データを分析するシステム、方法及びコンピュータプログラム製品
US7883904B2 (en) * 2006-05-19 2011-02-08 The Cleveland Clinic Foundation Detection and monitoring of liver damage
ES2402142T3 (es) * 2007-11-02 2013-04-29 Metabolon, Inc. Biomarcadores para la enfermedad del hígado graso y métodos que utilizan los mismos
JP5567600B2 (ja) * 2009-02-06 2014-08-06 メタボロン インコーポレイテッド 薬剤の肝毒性の判定
EP2309276A1 (en) * 2009-09-22 2011-04-13 One Way Liver Genomics, S.L. Method for the diagnosis of non-alcoholic steatohepatitis based on a metabolomic profile
US20120197539A1 (en) * 2009-10-09 2012-08-02 Carolyn Slupsky Methods for diagnosis, treatment and monitoring of patient health using metabolomics
WO2012000770A1 (en) * 2010-06-10 2012-01-05 Metanomics Health Gmbh Methods to diagnose liver diseases
US20130276513A1 (en) * 2010-10-14 2013-10-24 The Regents Of The University Of California Methods for diagnosing and assessing kidney disease
EP2776832A4 (en) * 2011-11-11 2015-06-03 Metabolon Inc BIOMARKER FOR BUBBLE CANCER AND METHOD FOR ITS USE
WO2015042602A1 (en) * 2013-09-23 2015-03-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Biomarkers related to organ function
CA2945165A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment

Similar Documents

Publication Publication Date Title
JP2016520192A5 (enExample)
JP2015064362A5 (enExample)
You et al. Tear fluid protein biomarkers
WO2018072862A8 (de) Verfahren zum auswerten von daten einer massenspektrometrie und massenspektrometrisches verfahren sowie ein maldi tof massenspektrometer
BR112017025097A2 (pt) método para quantificação espectrométrica de massa de analitos extraídos de um dispositivo de microamostragem
Beretov et al. Proteomics for breast cancer urine biomarkers
JP2020056595A5 (enExample)
WO2019028470A3 (en) Sequencing output determination and analysis with target-associated molecules in quantification associated with biological targets
MX2015013596A (es) Metodos, dispositivos y sistemas para analisis de muestras.
WO2015031676A3 (en) Integrity testing of hair samples
WO2018183966A3 (en) METHODS OF QUANTIFICATION OF INSULIN AND PEPTIDE C
JP2013517459A5 (enExample)
JP2017519989A5 (enExample)
JP2018528441A5 (enExample)
EP3465138A4 (en) SYSTEMS AND METHODS FOR ANALYZING AN ANALYTIC EXTRACTED FROM A SAMPLE WITH AN ADSORPTION MATERIAL
Frost et al. Recent advances in mass spectrometry-based glycoproteomics
EP3485258A4 (en) IMPROVED URINT STRIPS WITH LOW SAMPLES, ANALYSIS KITS, AND METHODS OF USE THEREOF
HK1254818A1 (zh) 抗原肽及其用於诊断和治疗自闭症的用途
BR112022008217A2 (pt) Métodos e dispositivos para sequenciamento
EP4054406A4 (en) SYSTEMS, DEVICE AND METHODS FOR ANALYZING SAMPLES
JP2015528562A5 (enExample)
WO2014151079A8 (en) Ratio based biomarkers and methods of use thereof for the detection and prognosis of cancer
JP2019007971A5 (enExample)
RU2014113841A (ru) Способ ранней диагностики эндогенной интоксикации
JP2016001137A5 (enExample)